Traws Pharma, Inc. announced that it has closed securities purchase agreement to issue 5,982,919 common shares at a price of $1.6730 per share for gross proceeds of $10,009,423.487, Series A warrants to initially purchase up to 5,982,919 shares of Common Stock, (iii) Series B warrants to initially purchase up to 5,982,919 shares of Common Stock, and (iv) Series C warrants to initially purchase up to 17,948,757 shares of Common Stock for aggregate proceeds of $60,000,000 on April 15, 2026. The exercise price per each Series A Warrant, Series B Warrant, and Series C Warrant is $1.673 a three-year term providing potential additional aggregate gross proceeds of approximately $30.0 million if fully exercised following shareholder approval. The Private Placement is expected to close on or about April 16, 2026.
The Common Stock, Warrants, and shares of Common Stock underlying the Warrants are being offered in reliance upon the exemption from the registration requirement of the Securities Act of 1933, as amended (the ?Securities Act?), pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D promulgated thereunder, and applicable state securities laws.